Inflammation markers and genes in atrial fibrillation prediction
Treatments studied
Part of Heart & circulation clinical trials.
This trial looks at whether certain blood markers and genetic information can help predict atrial fibrillation (irregular heartbeat). It studies how inflammation might play a role, and aims to find better ways to identify people at risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of atrial fibrillation (irregular heartbeat) that lasts for more than a week or needs treatment to stop.
- You are 18 years old or older.
- You do not have any autoimmune disease, inflammatory condition, liver problems, ongoing infection, thyroid disorder, or other conditions that affect inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a person’s genetics may affect how well and safely antiarrhythmic medicines work for atrial fibrillation (AF). If you join, you may get medicine options like flecainide or sotalol, and researchers compare outcomes to genetic information.
This study looks at early changes in the heart related to atrial fibrillation (AF) using health data and biomarkers. It aims to find better ways to predict or understand AF, especially around procedures like ablation or cardioversion.
This study measures changes in inflammation in people with atrial fibrillation (AF) who are getting a catheter ablation procedure. It may help doctors better understand what happens in the body during the procedure and why some patients do better than others.
This study looks at how to better judge a person’s risk of developing atrial fibrillation, a type of irregular heartbeat. You may help researchers by completing interviews and assessments that guide future risk estimates.
This study looks at how to better predict both stroke risk and bleeding risk in people with atrial fibrillation. It may help doctors choose safer blood-thinner treatment and follow-up plans.
This registry study follows people with atrial fibrillation to learn which risk factors are linked to stroke or blood clots traveling through the body. Your information helps improve how doctors predict risk and choose prevention strategies.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.